melphalan + methylprednisolone + pamidronate

**melphalan + methylprednisolone + pamidronate** is a three-drug combination used primarily for the treatment of multiple myeloma, especially in elderly patients and those not eligible for high-dose chemotherapy or stem cell transplant. - **Melphalan** is an alkylating chemotherapy agent that crosslinks DNA, inhibiting both DNA and RNA synthesis, leading to cytotoxicity in dividing and non-dividing tumor cells[7]. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid, acting as a potent anti-inflammatory and immunosuppressive agent; its primary effect in myeloma is to induce apoptosis in lymphoid cells and plasma cells. - **Pamidronate** is a bisphosphonate that inhibits osteoclast-mediated bone resorption and induces apoptosis in hematopoietic tumor cells, thereby reducing skeletal complications, bone pain, and hypercalcemia in myeloma patients[6][9][17]. This regimen targets malignant plasma cells and helps prevent bone destruction and symptomatic hypercalcemia, providing both antineoplastic and supportive care effects. This combination may be chosen in therapy protocols where bone involvement and hypercalcemia are present[13][17].

Other names

melphalan + methylprednisolone + pamidronate